NASDAQ:VRCA Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis $7.24 -0.01 (-0.14%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$7.01▼$7.3450-Day Range$7.04▼$9.1552-Week Range$2.86▼$11.41Volume156,441 shsAverage Volume192,677 shsMarket Capitalization$307.12 millionP/E RatioN/ADividend YieldN/APrice Target$13.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Verrica Pharmaceuticals alerts: Email Address Verrica Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside84.2% Upside$13.33 Price TargetShort InterestBearish15.37% of Float Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment0.31Based on 7 Articles This WeekInsider TradingSelling Shares$408,986 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.57) to ($0.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.92 out of 5 starsMedical Sector220th out of 936 stocksPharmaceutical Preparations Industry94th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingVerrica Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVerrica Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Verrica Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.37% of the float of Verrica Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVerrica Pharmaceuticals has a short interest ratio ("days to cover") of 17.1, which indicates bearish sentiment.Change versus previous monthShort interest in Verrica Pharmaceuticals has recently increased by 1.28%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVerrica Pharmaceuticals does not currently pay a dividend.Dividend GrowthVerrica Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVerrica Pharmaceuticals has received a 75.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Verrica Pharmaceuticals is -0.67. Previous Next 1.8 News and Social Media Coverage News SentimentVerrica Pharmaceuticals has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Verrica Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for VRCA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Verrica Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verrica Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $408,986.00 in company stock.Percentage Held by Insiders42.60% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.45% of the stock of Verrica Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verrica Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Verrica Pharmaceuticals are expected to grow in the coming year, from ($1.57) to ($0.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verrica Pharmaceuticals is -4.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verrica Pharmaceuticals is -4.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerrica Pharmaceuticals has a P/B Ratio of 15.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Verrica Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Verrica Pharmaceuticals Stock (NASDAQ:VRCA)Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.Read More VRCA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VRCA Stock News HeadlinesJuly 24 at 5:34 AM | insidertrades.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Insider Joe Bonaccorso Sells 25,461 SharesJuly 24 at 8:13 AM | americanbankingnews.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Insider Joe Bonaccorso Sells 25,461 Shares of StockJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 24 at 5:45 AM | americanbankingnews.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) CEO Ted White Sells 32,469 SharesJuly 15, 2024 | investorplace.com7 Short-Squeeze Stocks That Could Beat Down the BearsJuly 1, 2024 | globenewswire.comVerrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.May 30, 2024 | globenewswire.comVerrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New YorkMay 15, 2024 | markets.businessinsider.comVerrica Pharma Enters Amendment To License Agreement With Torii PharmaJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 15, 2024 | finance.yahoo.comVerrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common WartsMay 15, 2024 | globenewswire.comVerrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common WartsMay 14, 2024 | msn.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comVerrica Pharmaceuticals Inc (VRCA) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verrica Pharmaceuticals on Strong Ycanth Sales and Strategic Growth ProspectsMay 13, 2024 | markets.businessinsider.comStrong Buy Rating for Verrica Pharmaceuticals as Ycanth Launch Exceeds ExpectationsMay 13, 2024 | finanznachrichten.deVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 13, 2024 | finance.yahoo.comVerrica Pharmaceuticals Inc (VRCA) Reports Q1 2024 Results: A Detailed Financial ReviewMay 13, 2024 | globenewswire.comVerrica Pharmaceuticals Reports First Quarter 2024 Financial ResultsSee More Headlines Receive VRCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VRCA CUSIPN/A CIK1660334 Webwww.verrica.com Phone(434) 453-3300FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$13.33 High Stock Price Target$16.00 Low Stock Price Target$10.00 Potential Upside/Downside+85.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,000,000.00 Net Margins-905.83% Pretax Margin-905.83% Return on Equity-229.26% Return on Assets-88.77% Debt Debt-to-Equity Ratio29.58 Current Ratio3.17 Quick Ratio3.04 Sales & Book Value Annual Sales$5.12 million Price / Sales59.65 Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / Book15.32Miscellaneous Outstanding Shares42,420,000Free Float24,349,000Market Cap$305.42 million OptionableOptionable Beta1.56 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Ted White (Age 59)President, CEO & Director Comp: $914.68kMr. Christopher G. Hayes (Age 60)Chief Legal Officer, Secretary, Chief Compliance Officer & General Counsel Comp: $607.38kMr. Joe Bonaccorso (Age 60)Chief Commercial Officer Comp: $635.38kMr. P. Terence KohlerChief Financial OfficerDr. Gary Goldenberg M.D. (Age 47)Chief Medical Officer Comp: $553.03kMr. Eugene ScavolaExecutive Vice President of Technical OperationsDr. Bradley J. Catalone MBAPh.D., Head of Drug DevelopmentMore ExecutivesKey CompetitorsNature's Sunshine ProductsNASDAQ:NATRChimerixNASDAQ:CMRXFortress BiotechNASDAQ:FBIOOcular TherapeutixNASDAQ:OCULXencorNASDAQ:XNCRView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 4,393 shares on 7/26/2024Ownership: 0.138%Ted WhiteSold 32,469 sharesTotal: $229,231.14 ($7.06/share)Joe BonaccorsoSold 25,461 sharesTotal: $179,754.66 ($7.06/share)Miracle Mile Advisors LLCSold 34,221 shares on 7/18/2024Ownership: 0.198%SteelPeak Wealth LLCSold 15,100 shares on 7/17/2024Ownership: 0.290%View All Insider TransactionsView All Institutional Transactions VRCA Stock Analysis - Frequently Asked Questions How have VRCA shares performed this year? Verrica Pharmaceuticals' stock was trading at $7.32 on January 1st, 2024. Since then, VRCA shares have decreased by 1.1% and is now trading at $7.24. View the best growth stocks for 2024 here. How were Verrica Pharmaceuticals' earnings last quarter? Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) posted its quarterly earnings results on Monday, May, 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.10. The business had revenue of $3.83 million for the quarter, compared to the consensus estimate of $2.70 million. Verrica Pharmaceuticals had a negative net margin of 905.83% and a negative trailing twelve-month return on equity of 229.26%. When did Verrica Pharmaceuticals IPO? Verrica Pharmaceuticals (VRCA) raised $75 million in an initial public offering on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO. Who are Verrica Pharmaceuticals' major shareholders? Top institutional shareholders of Verrica Pharmaceuticals include SteelPeak Wealth LLC (0.29%), Miracle Mile Advisors LLC (0.20%) and Bank of New York Mellon Corp (0.14%). Insiders that own company stock include Paul B Manning, Perceptive Advisors Llc, Ted White, Joe Bonaccorso and Christopher G Hayes. View institutional ownership trends. How do I buy shares of Verrica Pharmaceuticals? Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Verrica Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verrica Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Novan (NOVN), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), CBL & Associates Properties (CBL) and This page (NASDAQ:VRCA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
